Guilin Sanjin Group

The late founder Zou Jieming consolidated ownership among his wife Weng Shizhen and three sons. Zou Xun, the eldest son, serves as Chairman and President of both the holding group and the listed pharmaceutical entity. Vice Chairman Zou Hong and Vice President Zou Zhun — who runs the Shanghai biotech operations — round out the family investment committee. There is no disclosed external advisory board or institutional investment committee.

Guilin Sanjin Group is the controlling shareholder of Guilin Sanjin Pharmaceutical Co., Ltd. (SZ: 002275), which listed on the Shenzhen Stock Exchange in 2009. The listed entity contains the branded Chinese patent medicine business — including the Sanjin Pian and Watermelon Frost product lines — while the unlisted holding company also holds the group's real estate assets and Shanghai biotech subsidiaries.

There is no public record of the group committing capital to third-party private equity or venture capital funds. Investment activity appears restricted to organic reinvestment in wholly owned pharmaceutical subsidiaries, the Sanjin Modern Chinese Medicine City project in Lingui District, and Guilin commercial real estate. The group has not disclosed family office allocations to external managers.

The Zou family's wealth originates from branded over-the-counter traditional Chinese medicine. Watermelon Frost lozenges and Sanjin Pian tablets — both nationally recognized brand names in China — generate the majority of operating cash flow. Founder Zou Jieming acquired the formerly state-owned enterprise during China's reform-era privatizations and later took the pharmaceutical division public in 2009.

Yes. The Sanjin Charity Foundation serves as the family's philanthropic vehicle, primarily funding health and education initiatives in the Guangxi region. It operates as a legally separate entity from the holding company and the listed pharmaceutical subsidiary, following China's foundation registration requirements.

Zou Jieming died in 2021. He had already installed his three sons in senior operating roles — Zou Xun as the listed company's Chairman, Zou Hong as group Vice Chairman, and Zou Zhun as Vice President over Shanghai biotech operations. The founder's widow, Weng Shizhen, retained a significant individual shareholding. No public boardroom dispute or equity restructuring followed the transition.

The group does not invest in early-stage technology startups, Western pharmaceutical drug development outside traditional Chinese medicine frameworks, or any sector outside its core pharma-real estate dual mandate. There is also no record of cross-border direct investments, external minority co-investments alongside other family offices, or commitments to blind-pool private equity funds.